Hellenic Oncology Research Group
60
1
1
36
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
30.0%
18 terminated/withdrawn out of 60 trials
66.7%
-19.8% vs industry average
23%
14 trials in Phase 3/4
0%
0 of 36 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (60)
An International Study on Pediatric Patients With Rare Tumors.
Role: collaborator
Male Breast Cancer: Understanding the Biology for Improved Patient Care
Role: collaborator
Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC
Role: lead
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
Role: lead
NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy"
Role: lead
Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer
Role: lead
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
Role: lead
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Role: lead
Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer
Role: lead
Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer
Role: lead
Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer
Role: lead
Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer
Role: lead
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Role: lead
Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer
Role: lead
Pazopanib in Relapsed and Refractory Small Cell Lung Cancer
Role: lead
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Role: lead
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Role: lead
Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer
Role: lead
Myocet Plus Endoxan for Older Patients With Breast Cancer
Role: lead
Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer
Role: lead